An immunohistochemical analysis of cyclin D1, p53. and p21waf1/cip1 proteins in tumors originating from the follicular epithelium of the thyroid gland

被引:22
作者
Goto, A
Sakamoto, A
Machinami, R
机构
[1] Kyorin Univ, Sch Med, Dept Pathol, Tokyo 1818611, Japan
[2] Kawakita Gen Hosp, Dept Pathol, Tokyo, Japan
关键词
thyroid tumor; immunohistochemistry; cyclin D1; p53; p21(waf1/cip1);
D O I
10.1078/0344-0338-00037
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study aimed at clarifying the factors closely related to the tumor progression of thyroid neoplasms. We examined the immunoreactivity of cyclin D1, p53, and p21(waf1/cip1) proteins in 179 thyroid tumors originating from the follicular epithelium using an immunohistochemical technique. Cyclin D1 positivity was frequent in well-differentiated thyroid carcinomas (39/122 cases), but it was rarely seen in follicular adenomas (1/33 cases), (p < 0.05). Positivity for p53 was more frequent in poorly differentiated carcinomas (7/19 cases) and undifferentiated carcinomas (4/5 cases) than in well-differentiated carcinomas (14/122 cases) (p < 0,05, respectively). P21(waf1/cip1) positivity was more frequent in well-differentiated thyroid carcinomas (43/122 cases) than in follicular adenomas (4/33 cases) (p < 0.05). Regarding the relationships of these proteins, co-positivity for cyclin D1 and p53 was observed more often in poorly differentiated carcinomas (5/7 cases) than in well-differentiated carcinomas (7/39 cases) (p < 0.05). Most cases with cyclin D1 positivity did not show p21(waf1/cip1) expression in poorly differentiated carcinomas (6/7 cases). Three cases examined showed co-positivity of p53 and p21(waf1/cip1). Our results suggest that cyclin D1 is invoved in thyroid oncogenesis. Moreover, p53 might be closely related to the development of poorly differentiated carcinomas and undifferentiated carcinomas originating from well-differentiated carcinomas.
引用
收藏
页码:217 / 222
页数:6
相关论文
共 32 条
  • [1] CYCLIN D1 PROTEIN-ANALYSIS IN THE DIAGNOSIS OF MANTLE CELL LYMPHOMA
    DEBOER, CJ
    SCHUURING, E
    DREEF, E
    PETERS, G
    BARTEK, J
    KLUIN, PM
    VANKRIEKEN, JHJM
    [J]. BLOOD, 1995, 86 (07) : 2715 - 2723
  • [2] OVEREXPRESSION OF P53 AS A POSSIBLE PROGNOSTIC FACTOR IN HUMAN THYROID-CARCINOMA
    DOBASHI, Y
    SAKAMOTO, A
    SUGIMURA, H
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1993, 17 (04) : 375 - 381
  • [3] STEPWISE PARTICIPATION OF P53 GENE MUTATION DURING DEDIFFERENTIATION OF HUMAN THYROID CARCINOMAS
    DOBASHI, Y
    SUGIMURA, H
    SAKAMOTO, A
    MERNYEI, M
    MORI, M
    OYAMA, T
    MACHINAMI, R
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (01) : 9 - 14
  • [4] WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION
    ELDEIRY, WS
    TOKINO, T
    VELCULESCU, VE
    LEVY, DB
    PARSONS, R
    TRENT, JM
    LIN, D
    MERCER, WE
    KINZLER, KW
    VOGELSTEIN, B
    [J]. CELL, 1993, 75 (04) : 817 - 825
  • [5] p53 and translational control
    Ewen, ME
    Miller, SJ
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1996, 1242 (03): : 181 - 184
  • [6] GREENBLATT MS, 1994, CANCER RES, V54, P4855
  • [7] Hedinger CE, 1974, HISTOLOGICAL TYPING
  • [8] Hosokawa Y, 1998, GENE CHROMOSOME CANC, V22, P66, DOI 10.1002/(SICI)1098-2264(199805)22:1<66::AID-GCC9>3.0.CO
  • [9] 2-5
  • [10] Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues
    Ito, Y
    Kobayashi, T
    Takeda, T
    Komoike, Y
    Wakasugi, E
    Tamaki, Y
    Tsujimoto, M
    Matsuura, N
    Monden, M
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 (08) : 1269 - 1274